asco.org1 天
Clinical outcomes after intensive VDT-PACE therapy for relapsed multiple myeloma.
This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...
asco.org1 天
Washington University experience with FOLFIRINOX in pancreatic cancer.
This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...
asco.org1 天
A phase II study of ERK inhibition by ulixertinib (BVD-523) in metastatic uveal melanoma.
This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...
asco.org2 天
Relevance of MIA and S-100 to monitor BRAF inhibitor (iBRAF) therapy in metastatic melanoma ...
This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...
asco.org2 天
Phase I dose-escalation and pharmacokinetic (PK) study of regorafenib in pediatric patients ...
This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...
asco.org1 天
Stability of rare TP53 co-mutations in AML patients.
This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...
asco.org2 天
Tumor mutation burden and PD-L1 expression in SDH/FH mutated solid tumors.
This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...
asco.org2 天
Association of a prostate cancer gastrointestinal transcriptional phenotype as found in ...
This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...
asco.org2 天
Interim safety and efficacy results from a phase 1 study of NT219 in adults with advanced ...
This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...
asco.org2 天
Phase 1 studies of personalized neoantigen vaccine TG4050 in ovarian carcinoma (OC) and ...
This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...
asco.org2 天
Cetuximab in first-line treatment of metastatic colorectal cancer in a real-life setting ...
This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...
asco.org2 天
A phase 1b study of ONT-380, an oral HER2-specific inhibitor, combined with capecitabine ...
This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...